Drug intelligence / Profile preview

PF-07985045 + PF-07284892

Development stage: Discontinued
Lead developer: Pfizer
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

PF-07985045 + PF-07284892 is a combination investigational therapy being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, including colorectal cancer and other KRAS mutation-related tumors. PF-07985045 is a small molecule inhibitor targeting KRAS, while PF-07284892 is a small molecule inhibitor targeting SHP2 (Src homology phosphotyrosyl phosphatase 2). The combination aims to overcome bypass signaling mechanisms and drug resistance in tumors where neither agent is effective as a single agent. Both drugs are orally administered and developed by Pfizer[1][2][3][4][5][7][9].

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)PTPN11 (Tyrosine-protein phosphatase non-receptor type 11)

Beyond the preview

Go deeper on PF-07985045 + PF-07284892.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-07985045 + PF-07284892.